Recurrent Diffuse Intrinsic Pontine Glioma
7
3
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (7)
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
Combination Therapy for the Treatment of Diffuse Midline Gliomas
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors
Hypofractionated Radiotherapy for Recurrent DIPG
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors